Fulgent Therapeutics
Temple City · Founded 2011
About Fulgent Therapeutics
Fulgent Therapeutics was issued its CLIA license (CLIA 05D2043189/CLF 00342581). Apart from traditional single gene tests, Fulgent Therapeutics has been investing heavily in the future. Using Next Generation Sequencing (NGS) technology we are developing a new series of panel based tests for our clients.
Company Facts
- Founded: 2011
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $100K – $500K
- Total funding: $34.8M
- Funding stage: IPO
- Last round: Series Unknown (May 2016)
- Ticker: nasdaq:FLGT
- Website: fulgentgenetics.com
- Phone: 626-350-0537
Industries & Categories
Biotechnology, Genetics, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/fulgent-therapeutics-60773 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.